Jackie Fielding joins Ossiform® Board of Directors
Ossiform Ltd. & Ossiform ApS
85 Great Portland Street, London, England, W1W 7LT
Oslogade 1, 5000 Odense, Denmark
LONDON, February 27, 2025 – Ossiform®, We Print Bone™, is pleased to announce the appointment of Jackie Fielding as Director for Ossiform Ltd. Jackie brings a wealth of expertise in medical device commercialization, with over 30 years of experience in commercial operations, strategy, and leadership.
Jackie is currently employed as Non-executive Director at NICE UK – the National Institute for Health and Care Excellence. Prior to joining NICE, Jackie advanced her career through 18 years at Medtronic Ltd., including as Regional Vice President for more than 10 years.
“I had the great pleasure to work with Jackie Fielding in the European leadership team in Medtronic over 13 years. Jackie is an extremely capable, highly respected and competent leader with unmatched expertise in the Medtech market, – Nationally as well as Internationally. I am very happy and honored that she has agreed to support us in Ossiform and look forward to our collaboration on making Ossiform a success. I wish Jackie a warm welcome”, says Mette-Marie Harild, Chairman of the board of directors, Ossiform Ltd. and Ossiform ApS.
“I am delighted and honored to be joining Ossiform as a Non Executive Director. I am excited by the technology and the impact it can have on the medical community and patients. I very much look forward to supporting this fantastic team on their exciting journey”, Jackie Fielding says.
Ossiform® is 3D printing bone-like, patient-matched and bio-integrative bone implants to advance bone healing outcomes and reduce complication rates in orthopedics and spine. The Company has a proven technology and value proposition, an ISO 13485 certified clean room production and QMS established, a worldwide patent portfolio, a highly experienced team, collaborations with clinical key opinion leaders from esteemed medical and research institutions and supplies bone-mimicking R&D products to laboratories worldwide.
Anticipating FDA clearance of the first P3D Bone graft substitutes for extremity and pelvis surgery within the next 12 months, Ossiform® is poised to enter the U.S. orthopedic bone graft market early next year. Meanwhile, the Company is developing the next generation of bio-integrative spinal fusion devices and Point of Care (PoC) bone printing solutions.
About Ossiform®
Ossiform® is dedicated to improving the lives of people with bone defects. We 3D print bio-integrative and patient-matched ceramic bone implants to reduce complications, improve functional outcomes, and obtain faster recovery.
We are continuously working to redefine bone replacements through progressive research and close collaboration with physicians and industry partners. Our patient-centric approach and commitment to innovation, quality, and progress steer our efforts to provide best-in-class implant solutions that facilitate the natural forming of new bone.
Website: www.ossiform.com
LinkedIn: Ossiform
For more information, please contact:
Thea Wulff Olesen, Group CEO
two@ossiform.com / +45 53 60 06 70